Clofibrate

氯贝丁酯

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameClofibrate
Drug Alias Name祛脂乙酯clofibrate降固醇酸clofibrato肉桂嗪 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemias +[8] 
Global Approved IndicationsHypertriglyceridemiaHypercholesterolemiaHyperlipidemias
Approved Indications in ChinaHypertriglyceridemiaHyperlipidemias
Original Approved Country/TerritoryUnited States
Original Approved Date1967/02/08
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesShaanxi Xiyue Pharmaceutical Co Ltd
Inactive CompaniesWyeth-AyerstNational Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsHypertriglyceridemiaHyperlipidemias
Inactive IndicationsHypercholesterolemiaMyocardial InfarctionCoronary Disease +[6] 

Other Information

ATC CodeC10AB01
Related LinksWikipediaDrugBankKEGG